.png)
A new era for oral macrocycle drug discovery
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery using its nGen platform, which systematically designs and tests macrocyclic compounds called nCycles optimized for oral bioavailability and membrane permeability. The company's pipeline targets diseases historically treated with injectable biologics, aiming to provide accessible oral alternatives. Orbis combines high-throughput synthesis, proprietary DNA-encoded libraries of nearly 100 billion compounds, and deep learning to accelerate macrocycle medicine.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2025
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
